


For the last five years (2017-2021)

Cumulative achievements (2012-)

Number of clinical trials per year



Number of feasibility studies

| Type | 2017 | 2018 | 2019 | 2020 | 2021 |
|------------------------------------|------|------|------|------|------|
| Clinical trial availability | 10 | 13 | 11 | 11 | 7 |
| Patient survey in clinical setting | 0 | 3 | 2 | 0 | 2 |
| Resurvey of ongoing clinical trial | 0 | 2 | 2 | 1 | 1 |
| Patient referral | 0 | 0 | 1 | 0 | 1 |

Number of responses to feasibility study

| | 2017 | 2018 | 2019 | 2020 | 2021 |
|----------------------|-------|-------|-------|-------|-------|
| Subject institutions | 275 | 487 | 503 | 368 | 476 |
| Responses | 266 | 436 | 462 | 346 | 454 |
| Response rates | 96.7% | 89.9% | 91.8% | 94.0% | 95.4% |

Number of clinical trials

86 trials

- ✓ In progress : 39trials
- ✓ Completed : 43trials
- ✓ Development discontinued : 4trials

Examples of target indications


- Pulmonary arterial hypertension
- Pediatric neurogenic detrusor overactivity
- Hemophilia
- Retinopathy of prematurity
- Short stature due to growth hormone deficiency
- Heart failure
- Status epilepticus
- Spinal Muscular Atrophy
- Ulcerative colitis
- Glioma
- Thromboprophylaxis after Fontan surgery
- Reflux esophagitis, ulcer prophylaxis with NSAIDs
- Mucopolysaccharidosis type II
- Suppression of chronic lung disease in premature infants
- Juvenile idiopathic arthritis
- Hyperuricemia
- Diabetes mellitus
- Constipation
- Hepatic encephalopathy
- Severe asthma
- Atopic dermatitis
- Hypercholesterolemia
- Hypertension
- etc...

Number of approved medicines/devices

23 products

| Approval Status | Trade name (Target indication) |
|------------------|---|
| Approved in 2016 | Hemangioli (Infantile hemangioma), Autologous Cultured Epidermis; JACE (Giant congenital melanocytic nevi) |
| Approved in 2017 | Intuniv (Attention deficit hyperactivity disorder), Revatio (Pulmonary arterial hypertension), NORDITROPIN (Short stature due to Noonan syndrome) |
| Approved in 2018 | Nexium (Gastrointestinal Diseases), IBULIEF (Patent ductus arteriosus), ORENCIA (Juvenile idiopathic arthritis), ILARIS (Systemic juvenile idiopathic arthritis), Refixia (Hemophilia B), LORA-PITA (Status epilepticus), HEMLIBRA (Hemophilia A), Precedex (Pediatric subjects in the intensive care unit) |
| Approved in 2019 | Fiasp (Type 1 diabetes), Esperoct (Hemophilia A), LUCENTIS (Retinopathy of prematurity) |
| Approved in 2020 | BUCCOLAM (Epilepsy), Xarelto (Thrombosis), IZCARGO (Mucopolysaccharidosis type II) |
| Approved in 2021 | EVRYSDI (Spinal Muscular Atrophy), AZILVA (Hypertension), FENTOS Tapes (Cancer pain), Ngenla (Growth hormone deficiency short stature) |

Trials by clinical department



※) Excluding follow-up studies

<The others>

Infectious disease / Psychiatry / Intensive care unit / Neonatology
Plastic surgery / Genetic medicine / Neuro-oncology / Anesthesiology etc...